Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$9.121M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
715.35%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$6.361M
Q3 2024
Cash
Q3 2024
P/E
-0.3893
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Selling, General & Admin $4.234M $5.963M $2.098M $2.770M $2.120M $1.090M $230.0K $30.00K $20.00K $20.00K $20.00K
YoY Change -29.0% 184.22% -24.26% 30.66% 94.5% 373.91% 666.67% 50.0% 0.0% 0.0%
% of Gross Profit
Research & Development $5.696M $4.324M $2.839M $1.919M $1.092M $1.250M $1.250M
YoY Change 31.73% 52.31% 47.94% 75.73% -12.64% 0.0%
% of Gross Profit
Depreciation & Amortization $500.00 $510.00 $0.00 $0.00
YoY Change -1.96%
% of Gross Profit
Operating Expenses $9.930M $10.29M $7.441M $4.686M $3.210M $2.340M $230.0K $30.00K $20.00K $20.00K $20.00K
YoY Change -3.47% 38.25% 58.79% 46.0% 37.16% 917.39% 666.67% 50.0% 0.0% 0.0%
Operating Profit -$9.930M -$10.29M -$7.441M -$4.686M -$3.210M
YoY Change -3.47% 38.25% 58.79% 46.0%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Interest Expense $0.00 $5.000K $6.000K $30.00K $1.010M $0.00 $0.00 $0.00
YoY Change -100.0% -16.67% -80.0% -97.03%
% of Operating Profit
Other Income/Expense, Net $641.0K $204.0K $4.000K $31.00K $1.037M $30.00K
YoY Change 214.22% 5000.0% -87.1% -97.01% 3357.85%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Pretax Income -$9.289M -$10.08M -$4.035M -$4.650M -$2.170M -$2.340M -$230.0K -$30.00K -$20.00K -$20.00K -$20.00K
YoY Change -7.87% 149.89% -13.23% 114.29% -7.26% 917.39% 666.67% 50.0% 0.0% 0.0%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.289M -$10.08M -$7.437M -$4.655M -$2.172M -$2.340M -$230.0K -$30.00K -$20.00K -$20.00K -$20.00K
YoY Change -7.87% 35.58% 59.76% 114.3% -7.17% 917.39% 666.67% 50.0% 0.0% 0.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$3.14 -$3.56 -$1.809M -$1.253M -$1.000M -$229.0K -$26.35K -$3.927K -$3.120K -$6.515K -$6.515K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Cash & Short-Term Investments $10.43M $17.53M $24.11M $2.140M $4.420M $340.0K $570.0K $0.00 $20.00K $10.00K $10.00K
YoY Change -40.53% -27.29% 1026.78% -51.58% 1200.0% -40.35% -100.0% 100.0% 0.0%
Cash & Equivalents $2.815M $6.888M $12.16M $2.140M $4.420M $340.0K $570.0K $0.00 $20.00K $10.00K $10.00K
Short-Term Investments $7.611M $10.65M $11.95M $3.436M
Other Short-Term Assets $554.0K $789.0K $496.0K $200.0K $10.00K $40.00K $0.00 $0.00
YoY Change -29.78% 59.07% 148.0% 1900.0% -75.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.98M $18.32M $24.61M $2.340M $4.440M $400.0K $570.0K $0.00 $20.00K $10.00K $10.00K
YoY Change -40.07% -25.55% 951.67% -47.3% 1010.0% -29.82% -100.0% 100.0% 0.0%
Property, Plant & Equipment $21.00K $60.00K $81.00K $0.00 $0.00 $0.00 $0.00
YoY Change -65.0% -25.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $1.519M
YoY Change -100.0%
Other Assets $3.000K $3.000K $3.000K $189.0K
YoY Change 0.0% 0.0% -98.41%
Total Long-Term Assets $2.063M $2.102M $3.642M $2.040M $2.040M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -1.86% -42.28% 78.53% 0.0%
Total Assets $13.04M $20.42M $28.25M $4.380M $6.480M $400.0K $570.0K $0.00 $20.00K $10.00K $10.00K
YoY Change
Accounts Payable $1.238M $905.0K $975.0K $490.0K $350.0K $530.0K $30.00K $10.00K $0.00 $0.00 $0.00
YoY Change 36.8% -7.18% 98.98% 40.0% -33.96% 1666.67% 200.0%
Accrued Expenses $23.00K $40.00K $31.00K $28.00K
YoY Change -42.5% 29.03% 10.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.291M $998.0K $1.027M $500.0K $1.020M $530.0K $30.00K $20.00K $0.00 $0.00 $0.00
YoY Change 29.36% -2.82% 105.4% -50.98% 92.45% 1666.67% 50.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $23.00K $57.00K $67.00K
YoY Change -100.0% -59.65% -14.93%
Total Long-Term Liabilities $0.00 $23.00K $57.00K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change -100.0% -59.65%
Total Liabilities $1.291M $1.021M $1.084M $500.0K $1.020M $530.0K $30.00K $20.00K $0.00 $0.00 $0.00
YoY Change 26.44% -5.81% 116.8% -50.98% 92.45% 1666.67% 50.0%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $3.5505 Million

About ARTELO BIOSCIENCES, INC.

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 5 full-time employees. The company went IPO on 2015-10-13. The firm is focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system (ECS), a family of receptors and neurotransmitters that form a biochemical communication network throughout the body. The company is developing a dual cannabinoid (CB) agonist that targets both the CB1 and CB2 receptors. This synthetic small molecule program is a G protein-coupled receptor (GPCR) designated ART27.13. ART27.13 is a potential treatment for anorexia associated with cancer. Its second program ART26.12, is a small molecule lead product candidate from its platform of inhibitors of fatty acid binding proteins, notably Fatty Acid Binding Protein 5 (FABP5), which is undergoing pre-clinical research as a potential cancer therapeutic, for pain and inflammation, and in anxiety-related disorders, including post-traumatic stress disorder.

Industry: Pharmaceutical Preparations Peers: CLS Holdings USA, Inc. ADIAL PHARMACEUTICALS, INC. Emmaus Life Sciences, Inc. GB SCIENCES INC JOHNSON & JOHNSON RANGE IMPACT, INC. PALISADE BIO, INC. Petros Pharmaceuticals, Inc.